Depression Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The depression therapeutics market size is expected to increase from USD 15.77 billion in 2025 to USD 16.45 billion in 2026 and reach USD 20.60 billion by 2031, growing at a CAGR of 4.60% over 2026-2031. This report is segmented by Drug Class (SSRIs, Snris, Atypical Antidepressants,), Indication (MDD, PPD, Bipolar, Others), Product Type (Generic and Branded), Route (Oral, Intranasal, and More), Channel (Retail, Hospital, and More), End User (Hospitals, Clinics, and More), and Geography (North America, Europe, and More).

Global Depression Therapeutics Market Trends and Insights

Rising Diagnosis and Treatment Uptake for Major Depressive Disorder

Major depressive disorder remains the main volume driver for the Depression therapeutics market, although better primary care detection now matters more than incidence alone. An estimated 21 million U.S. adults experienced at least 1 major depressive episode annually by early 2025, while nearly 1 in 3 received no treatment. This diagnosed but untreated group can expand use without requiring higher disease incidence, especially where primary care screening, referral systems, and follow-up are improving across routine care settings. Patients who fail several oral treatments also create demand for alternatives, since 86% of those trying a third oral antidepressant did not achieve remission. A 2025 systematic review identified 18 compounds in global Phase 3 trials, with a wider range of mechanisms than earlier antidepressant development programs. European SSRI consumption rose by 3.7 to 14.4 defined daily doses per 1,000 inhabitants per day across 8 measured markets from 2013 to 2023, showing that access and lower stigma can increase treatment volume

Expansion of Rapid-Acting and Novel-Mechanism Therapies

Rapid-acting therapies are expanding the Depression therapeutics market because they address patients who have not responded to standard oral treatment. The FDA approved Spravato as the first and only monotherapy for adults with treatment-resistant depression in January 2025, based on evidence of symptom relief that could appear within 24 hours. Monotherapy removes the need to continue an oral antidepressant alongside esketamine, which may reduce a practical barrier for patients with prior treatment failures. Compass Pathways stated in April 2026 that the FDA granted rolling NDA review for COMP360 and awarded a Commissioner’s National Priority Voucher, with a planned NDA completion in Q4 2026. The company reported 2 positive Phase 3 trials involving more than 1,000 treatment-resistant depression patients and 26-week durability data. Breakthrough Therapy and REMS requirements also shape launch planning, define provider obligations, and help support premium positioning for approved novel agents.

Generic Substitution and Pricing Pressure in First-Line Antidepressants

Generic substitution constrains revenue growth in the Depression therapeutics market because SSRIs and SNRIs remain the first treatment option for many patients. A 2024 Brookings analysis reported annual acquisition-cost deflation of 10% to 15% for generic oral solids. This creates pressure on manufacturers that continue to depend on off-patent products. France’s medicines agency reported 14 supply tensions or stock-outs for psychotropic medicines between January and mid-2025, including sertraline, quetiapine, and venlafaxine. The report linked shortages to the commoditization of production. In the United States, generic citalopram was available for USD 4 to USD 15 for a 30-day supply in 2026, leaving little room for branded first-line pricing. Companies with an older product mix must therefore balance high volumes against continued margin pressure.

Other drivers and restraints analyzed in the detailed report include:

• Growing Screening and Treatment of Postpartum Depression
• Increasing Mental Health Awareness and Reduction in Treatment Stigma
• Safety Monitoring and Controlled-Administration Requirements

Segment Analysis

SSRIs held 34.8% of the Depression therapeutics market in 2025, supported by first-line guidelines, broad formulary access, and low generic prices. Sertraline, escitalopram, and fluoxetine account for a substantial share of prescriptions. Their role gives the Depression therapeutics industry a high-volume base, although revenue per prescription remains low. SNRIs are the second-largest drug class by revenue, while atypical antidepressants and atypical antipsychotics serve patients who need alternatives or adjunct treatment.

NMDA and novel rapid-acting therapies are forecast to grow at a 12.8% CAGR through 2031, the highest rate within drug classes. Spravato’s 2025 monotherapy label and the COMP360 rolling NDA review show the move toward premium treatments for treatment-resistant depression. The 2025 review described late-stage programs across NMDA modulation, GABA-A modulation, orexin-2 antagonism, and Kv7 potassium channel opening. Tricyclics and MAOIs continue to decline because safety concerns and dietary restrictions limit use. REMS and Breakthrough Therapy frameworks set important commercialization milestones for new products.

Major depressive disorder accounted for 67.4% of the Depression therapeutics market size in 2025. Its breadth and role as the main initial approval pathway make it the central revenue source. New drug classes commonly establish evidence in MDD before pursuing treatment-resistant, bipolar, or other labels. Bipolar depression is the third-largest revenue pool, while smaller indications include seasonal affective disorder, premenstrual dysphoric disorder, and depression linked to neurological conditions.

Postpartum depression is forecast to grow at a 10.9% CAGR through 2031, the fastest rate within indications. The rollout of zuranolone in the United States, United Kingdom, Europe, Canada, and Japan established a distinct oral treatment pathway. Clinical evidence from 346 patients showed improvement by day 3 and sustained benefit through day 45. The withdrawal of brexanolone narrowed oral treatment choices and directed attention toward zuranolone. Underdiagnosis remains common in Asia and South America, so screening updates could make the accessible population larger than current treated volumes indicate.

Complete Report Scope:

• By Drug Class
  • SSRIs
  • SNRIs
  • Atypical Antidepressants
  • Tricyclic & MAOI Antidepressants
  • Atypical Antipsychotics
  • NMDA & Novel Rapid-Acting Therapies
  • Other Depression Therapeutics
• By Indication
  • Major Depressive Disorder (MDD)
  • Postpartum Depression
  • Bipolar Depression
  • Other Depression Indications
• By Product Type
  • Generic Therapies
  • Branded Therapies
• By Route of Administration
  • Oral
  • Intranasal
  • Injectable (IV/IM/SC)
  • Transdermal & Other Routes
  • Digital Delivery
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
  • Other Channels
• By End User
  • Hospitals
  • Specialty Mental Health Clinics
  • Primary Care Practices
  • Outpatient Psychiatric Practices
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.5% of the depression therapeutics market share in 2025. High treatment penetration, a large novel-drug pipeline, and faster reimbursement pathways for branded and interventional therapies support this position. The United States generates most regional revenue and has many specialty clinics offering esketamine, TMS, and digital therapeutic prescriptions. Canada approved zuranolone in December 2025, making it the first postpartum depression-specific oral therapy available in the country, while Mexico has limited specialist capacity and generic-first formulary restrictions.

Europe is the second-largest regional contributor to the Depression therapeutics market. Zuranolone received authorization in the European Union and the United Kingdom in 2025, creating the first oral postpartum depression treatment option in both settings. Antidepressant consumption is rising in most European markets, although 2030 growth expectations vary from 0.1% to 80.9%. Germany, France, and the United Kingdom are the largest revenue markets, while French prescription growth contributed to supply disruptions in 2025. Novel mechanisms can face longer access timelines than in the United States.

Asia-Pacific is forecast to grow at an 8.7% CAGR through 2031, the highest regional rate for the Depression therapeutics market. Improving infrastructure, a larger insured population, and public-health efforts underpin this pace. China has an estimated 54 million people with depression and is pursuing stronger mental health and digital health services for 2025 to 2027. Japan approved zuranolone in December 2025, while Australia added ketamine to the Pharmaceutical Benefits Scheme in May 2025 and has a supervised clinical context for psilocybin and MDMA. India’s urban-rural care gap and early-stage psychiatric infrastructure in the Middle East and Africa represent longer-term opportunities.

List of Companies Covered in this Report:

• Johnson & Johnson
• Eli Lilly and Company
• Pfizer
• Abbvie
• H. Lundbeck
• Otsuka
• Takeda Pharmaceuticals
• GlaxoSmithKline
• Bristol-Myers Squibb
• AstraZeneca
• Sanofi
• Teva Pharmaceutical Industries
• Viatris
• Sun Pharmaceuticals Industries
• Alkermes plc
• Neurocrine Biosciences
• Axsome Therapeutics
• Sage Therapeutics
• Biogen
• Acadia Pharmaceuticals Inc.
• Intra-Cellular Therapies, Inc.
• Compass Pathways plc
• Cybin Inc.
• atai Life Sciences N.V.
• MindMed Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support